Vaginal Dryness and Genitourinary Syndrome of Menopause

This is among the most undertreated problems in midlife medicine, largely because it is under-raised. Surveys consistently find that few women bring it up and few clinicians ask. The result is years of avoidable discomfort treated as an inevitability.

One difference that changes the decision

Vasomotor symptoms — hot flashes and night sweats — are usually self-limiting. They can last years, but they tend to diminish over time. Genitourinary symptoms behave differently: without treatment they tend to persist and progress, because the underlying tissue change continues.

That matters for how the choice is framed. “Wait and see whether this settles” is a reasonable stance for hot flashes. It is a much weaker stance here, because waiting is not neutral.

It is genital and urinary, and the urinary half gets missed

The name changed for a reason. The older term, vaginal atrophy, described only part of it. Genitourinary syndrome of menopause covers dryness, burning, irritation and pain with intercourse, and also urinary urgency, discomfort passing urine, and recurrent urinary tract infections.

The urinary symptoms are the ones most often treated in isolation — a woman may be managed for repeated urinary infections for years without anyone connecting them to the same underlying change. If you have both, say so in the same sentence at the same visit; they are one problem, not two coincidences.

What the evidence supports

The 2022 hormone therapy position statement of The North American Menopause Society states that hormone therapy “remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture.”

The important qualifier is which kind. Local vaginal treatment is delivered at much lower doses, directed at the tissue itself, and is considered separately from systemic therapy. A woman whose only troublesome symptom is genitourinary usually does not need systemic treatment for it — and the risk discussion that attaches to systemic estrogen does not transfer wholesale to low-dose local treatment. When you read a claim about the risks of “hormone therapy,” the first question is always which of the two it concerns.

The third category: prescription treatment

Moisturisers and lubricants are bought off the shelf. The treatment the position statement is referring to is a prescription one, and the usual first-line form is low-dose vaginal estrogen — estrogen delivered directly to the tissue rather than taken systemically, which is why it is discussed separately from systemic hormone therapy and why its dose is a fraction of the systemic one.

There are also non-estrogen prescription options for women who cannot or prefer not to use vaginal estrogen. Which category suits a particular woman, in which form, at what dose and for how long, is a prescribing decision and is not something to settle from an article — including this one.

The point of naming it is narrower: if daily moisturising and appropriate lubrication have not resolved things, the next conversation is about prescription treatment, and “is low-dose vaginal estrogen appropriate for me?” is a reasonable question to put directly to a clinician. A history of breast or other hormone-sensitive cancer changes that discussion and makes it one for the treating team — it does not automatically end it.

Moisturisers and lubricants are not the same thing

A lubricant used only during sex does not treat daily dryness, and a moisturiser is not a substitute for lubrication at the moment it is needed. Many women who conclude that non-prescription options failed have in fact been using one product for the other’s purpose, or using a moisturiser sporadically rather than on a schedule.

What to raise at a visit

• Whether the problem is dryness at rest, pain with intercourse, urinary symptoms, or a combination
• How long it has been going on, and whether it is getting worse
• What you have already tried, how often you used it, and for how long
• Whether you have had recurrent urinary infections
• Whether you have a history of breast or other hormone-sensitive cancer, which changes the discussion but does not automatically end it

What needs attention promptly

Vaginal bleeding after menopause always warrants evaluation, whether or not you are using any vaginal treatment. So do new pelvic pain, a lump or ulcer that does not heal, or fever with urinary symptoms.

Main takeaway

Genitourinary symptoms are not a phase to wait out. They are genital and urinary together, hormone therapy is the most effective treatment for them, and local treatment is a different proposition from systemic therapy. Before concluding that nothing works, check that a moisturiser was used on a schedule and a lubricant at the right moment — that alone changes the answer for many women.